Glucocorticoids attenuate the sensitivity of glucocorticoid-resistant lymphoid cells to doxorubicin via reduction in OCTN2
Glucocorticoid (GC) resistance is associated with poor response to the following chemotherapy in lymphoid malignancies, such as lymphoma and leukemia. However, it remains unclear whether GCs interfere with the cytotoxic effects of anti-cancer drugs on GC-resistant cells. In this study, we examined whether GCs affected the sensitivities to vincristine (VCR)/doxorubicin (DOX) and the expression of drug transporters in GC-resistant cells. The dexamethasone (DEX)/prednisolone (PSL)-resistant lymphoid and non-lymphoid cell lines Raji and HL60 were cultured with DEX for 7 days and then treated with VCR or DOX for 3 days. Seven days of DEX treatment increased the IC50s of both VCR and DOX in Raji cells but not in HL60 cells. The mRNA and protein expression levels of organic cation/carnitine transporter (OCTN) 2, one of the drug uptake transporters expressed in both cell lines, were decreased only in Raji cells. When Raji cells were cultured with PSL, the IC50 of DOX but not VCR increased as the expression of OCTN2 decreased. No significant increases in efflux transporter expression were induced by DEX or PSL. When siRNA against OCTN2 was introduced into Raji cells, the IC50 of DOX but not VCR increased significantly. These data suggested that both DEX and PSL decreased the sensitivity of the DEX/PSL-resistant Raji cells to DOX, a change that was at least partially due to reductions in OCTN2. Thus, the continuous usage of GCs may interfere with the effects of chemotherapy on GC-resistant lymphoid cells.
KeywordsGlucocorticoid Lymphoid malignancies Doxorubicin Transporter OCTN2
We would like to thank Ms. Michiko Anzai (Fukushima Medical University, Fukushima, Japan) for providing technical assistance.
MA analyzed cytotoxicity, expression of transporters, effects of siRNA, and YS designed and integrated the study. TO and YM contributed to flow cytometric analyses and cytotoxicity assay. JK and MH supervised the study design and data analyses.
This study was funded by grants from the Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research (C) MO23591400 to Y.S. and MO24590325 to J.K.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
In this study, neither human subjects nor animals were used.
- 3.Kato M, Koh K, Manabe A, Saito T, Hasegawa D, Isoyama K, Kinoshita A, Maeda M, Okimoto Y, Kajiwara M, Kaneko T, Sugita K, Kikuchi A, Tsuchida M, Ohara A (2014) No impact of high-dose cytarabine and asparaginase as early intensification with intermediate-risk paediatric acute lymphoblastic leukaemia: results of randomized trial TCCSG study L99-15. Br J Haematol 164:376–383. https://doi.org/10.1111/bjh.12632 CrossRefPubMedGoogle Scholar
- 4.Kato M, Manabe A, Koh K, Inukai T, Kiyokawa N, Fukushima T, Goto H, Hasegawa D, Ogawa C, Koike K, Ota S, Noguchi Y, Kikuchi A, Tsuchida M, Ohara A (2014) Treatment outcomes of adolescent acute lymphoblastic leukemia treated on Tokyo Children’s Cancer Study Group (TCCSG) clinical trials. Int J Hematol 100:180–187. https://doi.org/10.1007/s12185-014-1622-y CrossRefPubMedGoogle Scholar
- 5.Conter V, Arico M, Valsecchi MG, Basso G, Biondi A, Madon E, Mandelli F, Paolucci G, Pession A, Rizzari C, Rondelli R, Zanesco L, Masera G (2000) Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982–1995. Leukemia 14:2196–2204CrossRefPubMedGoogle Scholar
- 8.Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109:2773–2780. https://doi.org/10.1182/blood-2006-07-036673 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphael M, Terrier-Lacombe MJ (2001) The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multi agent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379CrossRefPubMedGoogle Scholar
- 10.Arico M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, Zanesco L, Rondelli R, Pession A, Masera G (1995) Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer 75:1684–1693CrossRefPubMedGoogle Scholar
- 13.Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V, Reiter A, Valsecchi MG, Gadner H, Basso G, Bartram CR, Lampert F, Riehm H, Masera G (1998) Philadelphia chromosome-positive (Ph +) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92:2730–2741PubMedGoogle Scholar
- 14.Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM (2007) Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood 109:926–935. https://doi.org/10.1182/blood-2006-01-024729 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Tsuchida M, Ikuta K, Hanada R, Saito T, Isoyama K, Sugita K, Toyoda Y, Manabe A, Koike K, Kinoshita A, Maeda M, Ishimoto K, Sato T, Okimoto Y, Kaneko T, Kajiwara M, Sotomatsu M, Hayashi Y, Yabe H, Hosoya R, Hoshi Y, Ohira M, Bessho F, Tsunematsu Y, Tsukimoto I, Nakazawa S (2000) Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children’s Cancer Study Group 1981–1995. Leukemia 14:2295–2306CrossRefPubMedGoogle Scholar
- 17.Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G (1987) Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 199:151–160. https://doi.org/10.1055/s-2008-1026781 CrossRefPubMedGoogle Scholar
- 18.Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, Burckhardt G, Hagos Y (2009) Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res 69:1494–1501. https://doi.org/10.1158/0008-5472.can-08-2483 CrossRefPubMedGoogle Scholar
- 19.Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM (2008) Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081–3091. https://doi.org/10.1158/1535-7163.mct-08-0539 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, Mizoi T, Shiiba K, Takanaga H, Terasaki T, Matsuno S, Sasaki I, Ito S, Abe T (2005) Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333:754–762. https://doi.org/10.1016/j.bbrc.2005.05.174 CrossRefPubMedGoogle Scholar
- 24.Gasser PJ, Lowry CA, Orchinik M (2006) Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci 26:8758–8766. https://doi.org/10.1523/jneurosci.0570-06.2006 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Manceau S, Giraud C, Decleves X, Batteux F, Chereau C, Chouzenoux S, Scherrmann JM, Weill B, Perrot JY, Treluyer JM (2012) Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line. J Chemother 24:48–55. https://doi.org/10.1179/1120009x12z.00000000010 CrossRefPubMedGoogle Scholar
- 27.Bachmann PS, Gorman R, Mackenzie KL, Lutze-Mann L, Lock RB (2005) Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 105:2519–2526. https://doi.org/10.1182/blood-2004-05-2023 CrossRefPubMedGoogle Scholar
- 28.Bachmann PS, Gorman R, Papa RA, Bardell JE, Ford J, Kees UR, Marshall GM, Lock RB (2007) Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res 67:4482–4490. https://doi.org/10.1158/0008-5472.can-06-4244 CrossRefPubMedGoogle Scholar
- 30.Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR, Armstrong SA (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10:331–342. https://doi.org/10.1016/j.ccr.2006.09.006 CrossRefPubMedGoogle Scholar
- 32.Piotrowska H, Jagodzinski PP (2007) Trichostatin A, sodium butyrate, and 5-aza-2′-deoxycytidine alter the expression of glucocorticoid receptor alpha and beta isoforms in Hut-78 T- and Raji B-lymphoma cell lines. Biomed Pharmacother 61:451–454. https://doi.org/10.1016/j.biopha.2007.03.007 CrossRefPubMedGoogle Scholar
- 37.Kolbus A, Blazquez-Domingo M, Carotta S, Bakker W, Luedemann S, von Lindern M, Steinlein P, Beug H (2003) Cooperative signaling between cytokine receptors and the glucocorticoid receptor in the expansion of erythroid progenitors: molecular analysis by expression profiling. Blood 102:3136–3146. https://doi.org/10.1182/blood-2003-03-0923 CrossRefPubMedGoogle Scholar
- 38.Koyama Y, Ukita A, Abe K, Iwamae K, Tokuyama S, Tanaka K, Kotake Y (2017) Dexamethasone downregulates endothelin receptors and reduces endothelin-induced production of matrix metalloproteinases in cultured rat astrocytes. Mol Pharmacol 92:57–66. https://doi.org/10.1124/mol.116.107300 CrossRefPubMedGoogle Scholar
- 39.Zadi Heydarabad M, Nikasa M, Vatanmakanian M, Azimi A, Farshdousti Hagh M (2018) Regulatory effect of resveratrol and prednisolone on MDR1 gene expression in acute lymphoblastic leukemia cell line (CCRF-CEM): an epigenetic perspective. J Cell Biochem 119:4890–4896. https://doi.org/10.1002/jcb.26709 CrossRefPubMedGoogle Scholar
- 41.Umsumarng S, Pitchakarn P, Sastraruji K, Yodkeeree S, Ung AT, Pyne SG, Limtrakul P (2015) Reversal of human multi-drug resistance leukaemic cells by stemofoline derivatives via inhibition of P-glycoprotein function. Basic Clin Pharmacol Toxicol 116:390–397. https://doi.org/10.1111/bcpt.12331 CrossRefPubMedGoogle Scholar
- 44.Kullmann MK, Grubbauer C, Goetsch K, Jakel H, Podmirseg SR, Trockenbacher A, Ploner C, Cato AC, Weiss C, Kofler R, Hengst L (2013) The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells. Cell Cycle 12:2625–2635. https://doi.org/10.4161/cc.25622 CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Wang HY, Zhang Y, Zhou Y, Lu YY, Wang WF, Xin M, Guo XL (2016) Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-gamma pathway. Biomed Pharmacother 83:349–361. https://doi.org/10.1016/j.biopha.2016.06.047 CrossRefPubMedGoogle Scholar
- 46.Sayed-Ahmed MM, Al-Shabanah OA, Hafez MM, Aleisa AM, Al-Rejaie SS (2010) Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur J Pharmacol 640:143–149. https://doi.org/10.1016/j.ejphar.2010.05.002 CrossRefPubMedGoogle Scholar